- |||||||||| Neulasta (pegfilgrastim) / Roche, Rituxan (rituximab) / Roche
Enrollment change, Combination therapy: Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma (clinicaltrials.gov) - Dec 16, 2013 P2, N=20, Active, not recruiting, Initiation date: Oct 2013 --> May 2014 N=40 --> 20
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial: Denosumab China Phase III Study (clinicaltrials.gov) - Dec 16, 2013 P3, N=444, Recruiting,
- |||||||||| Neulasta (pegfilgrastim) / Roche, Rituxan (rituximab) / Roche
Enrollment closed, Combination therapy: Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma (clinicaltrials.gov) - Dec 16, 2013 P2, N=20, Active, not recruiting, N=40 --> 20 Recruiting --> Active, not recruiting
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: Observational Study of Denosumab (Prolia (clinicaltrials.gov) - Dec 15, 2013 P=N/A, N=1501, Active, not recruiting, Active, not recruiting --> Completed Initiation date: Nov 2011 --> Nov 2012
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment change: Observational Study of Denosumab (Prolia (clinicaltrials.gov) - Dec 15, 2013 P=N/A, N=1501, Active, not recruiting, N=168 --> 120 N=1200 --> 1501
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Observational Study of Denosumab (Prolia (clinicaltrials.gov) - Dec 15, 2013 P=N/A, N=1501, Active, not recruiting, N=1200 --> 1501 Recruiting --> Active, not recruiting
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed, HEOR: Observational Study Evaluating Etanercept (Enbrel (clinicaltrials.gov) - Dec 15, 2013 P=N/A, N=800, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Simulect (basiliximab) / Novartis, Enbrel (etanercept) / Pfizer, Amgen, Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes (clinicaltrials.gov) - Dec 15, 2013 P2, N=14, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Kepivance (palifermin) / SOBI, Amgen
Enrollment closed, Metastases: Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Dec 10, 2013 P2, N=52, Active, not recruiting, Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment closed, Metastases: Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) (clinicaltrials.gov) - Dec 10, 2013 P1, N=21, Active, not recruiting, Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
|